Mitochondrial apoptosis-inducing factor is involved in doxorubicin-induced toxicity on H9c2 cardiomyoblasts

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 12, 2014, Pages 2468-2478

  Moreira, Ana C ^a,b   Branco, Ana F ^a,b   Sampaio, Susana F ^a,b   Cunha Oliveira, Teresa ^a   Martins, Tatiana R ^a,b   Holy, Jon ^c   Oliveira, Paulo J ^a   Sardão, Vilma A ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Apoptosis inducing factor; Cardiomyoblast; Doxorubicin

Indexed keywords

APOPTOSIS INDUCING FACTOR; CALPAIN; CASPASE 3; CASPASE INHIBITOR; CATHEPSIN B; CELL NUCLEUS DNA; DNA FRAGMENT; DOXORUBICIN; MITOCHONDRIAL APOPTOSIS INDUCING FACTOR; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; [1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER; ANTINEOPLASTIC ANTIBIOTIC; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; CASPASE; PEPTIDE CHLOROMETHYL KETONE;

ANIMAL CELL; ARTICLE; CARDIOTOXICITY; CELL DEATH; CELL FRACTIONATION; CELL NUCLEUS; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE SILENCING; GENE TRANSLOCATION; MITOCHONDRION; MYOBLAST; NONHUMAN; PROTEIN CLEAVAGE; WESTERN BLOTTING; ACTIVE TRANSPORT; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; CELL LINE; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HEART MUSCLE CELL; METABOLISM; RAT; RNA INTERFERENCE; TIME;

ACTIVE TRANSPORT, CELL NUCLEUS; AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS INDUCING FACTOR; BLOTTING, WESTERN; CASPASE INHIBITORS; CASPASES; CELL LINE; CELL NUCLEUS; CELL SURVIVAL; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; MICROSCOPY, CONFOCAL; MITOCHONDRIA; MODELS, BIOLOGICAL; MYOCYTES, CARDIAC; RATS; RNA INTERFERENCE; TIME FACTORS;

EID: 84910051188     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.09.015     Document Type: Article

References (67)

1. Booser D.J., Hortobagyi G.N. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 1994, 47:223-258.
2. Dessypris E.N., Brenner D.E., Hande K.R. Toxicity of doxorubicin metabolites to human marrow erythroid and myeloid progenitors in vitro. Cancer Treat. Rep. 1986, 70:487-490.
3. Cutts S.M., Nudelman A., Rephaeli A., Phillips D.R. The power and potential of doxorubicin-DNA adducts. IUBMB Life 2005, 57:73-81.
4. Cummings J., Anderson L., Willmott N., Smyth J.F. The molecular pharmacology of doxorubicin in vivo. Eur. J. Cancer 1991, 27:532-535.
5. Doroshow J.H., Davies K.J. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J. Biol. Chem. 1986, 261:3068-3074.
6. Davies K.J., Doroshow J.H. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem. 1986, 261:3060-3067.
7. Carvalho F.S., Burgeiro A., Garcia R., Moreno A.J., Carvalho R.A., Oliveira P.J. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med. Res. Rev. 2013, 34:106-135.
8. Vandecruys E., Mondelaers V., De Wolf D., Benoit Y., Suys B. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood. J. Cancer Surviv. 2012, 6:95-101.
9. Kumar S., Marfatia R., Tannenbaum S., Yang C., Avelar E. Doxorubicin-induced cardiomyopathy 17years after chemotherapy. Tex. Heart Inst. J. 2012, 39:424-427.
10. Bristow M.R., Minobe W.A., Billingham M.E., Marmor J.B., Johnson G.A., Ishimoto B.M., Sageman W.S., Daniels J.R. Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. Lab. Invest. 1981, 45:157-168.
11. Ueno M., Kakinuma Y., Yuhki K., Murakoshi N., Iemitsu M., Miyauchi T., Yamaguchi I. Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J. Pharmacol. Sci. 2006, 101:151-158.
12. Susin S.A., Daugas E., Ravagnan L., Samejima K., Zamzami N., Loeffler M., Costantini P., Ferri K.F., Irinopoulou T., Prevost M.C., Brothers G., Mak T.W., Penninger J., Earnshaw W.C., Kroemer G. Two distinct pathways leading to nuclear apoptosis. J. Exp. Med. 2000, 192:571-580.
13. Jang Y.M., Kendaiah S., Drew B., Phillips T., Selman C., Julian D., Leeuwenburgh C. Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Lett. 2004, 577:483-490.
14. Sardao V.A., Oliveira P.J., Holy J., Oliveira C.R., Wallace K.B. Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemother. Pharmacol. 2009, 64:811-827.
15. Kajihara H., Yokozaki H., Yamahara M., Kadomoto Y., Tahara E. Anthracycline induced myocardial damage. An analysis of 16 autopsy cases. Pathol. Res. Pract. 1986, 181:434-441.
16. Arola O.J., Saraste A., Pulkki K., Kallajoki M., Parvinen M., Voipio-Pulkki L.M. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000, 60:1789-1792.
17. Bernaba B.N., Chan J.B., Lai C.K., Fishbein M.C. Pathology of late-onset anthracycline cardiomyopathy. Cardiovasc. Pathol. 2010, 19:308-311.
18. Youn H.J., Kim H.S., Jeon M.H., Lee J.H., Seo Y.J., Lee Y.J. Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment. Mol. Cell. Biochem. 2005, 270:13-19.
19. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., Mangion J., Jacotot E., Costantini P., Loeffler M., Larochette N., Goodlett D.R., Aebersold R., Siderovski D.P., Penninger J.M., Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999, 397:441-446.
20. Sevrioukova I.F. Apoptosis-inducing factor: structure, function, and redox regulation. Antioxid. Redox Signal. 2011, 14:2545-2579.
21. Daugas E., Susin S.A., Zamzami N., Ferri K.F., Irinopoulou T., Larochette N., Prevost M.C., Leber B., Andrews D., Penninger J., Kroemer G. Mitochondrio-nuclear transl ocation of AIF in apoptosis and necrosis. FASEB J. 2000, 14:729-739.
22. Landshamer S., Hoehn M., Barth N., Duvezin-Caubet S., Schwake G., Tobaben S., Kazhdan I., Becattini B., Zahler S., Vollmar A., Pellecchia M., Reichert A., Plesnila N., Wagner E., Culmsee C. Bid-induced release of AIF from mitochondria causes immediate neuronal cell death. Cell Death Differ. 2008, 15:1553-1563.
23. Vosler P.S., Sun D., Wang S., Gao Y., Kintner D.B., Signore A.P., Cao G., Chen J. Calcium dysregulation induces apoptosis-inducing factor release: cross-talk between PARP-1- and calpain-signaling pathways. Exp. Neurol. 2009, 218:213-220.
24. Formentini L., Macchiarulo A., Cipriani G., Camaioni E., Rapizzi E., Pellicciari R., Moroni F., Chiarugi A. Poly(ADP-ribose) catabolism triggers AMP-dependent mitochondrial energy failure. J. Biol. Chem. 2009, 284:17668-17676.
25. Sardao V.A., Oliveira P.J., Holy J., Oliveira C.R., Wallace K.B. Vital imaging of H9c2 myoblasts exposed to tert-butylhydroperoxide-characterization of morphological features of cell death. BMC Cell Biol. 2007, 8:11.
26. L'Ecuyer T., Sanjeev S., Thomas R., Novak R., Das L., Campbell W., Heide R.V. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1273-H1280.
27. Sardao V.A., Oliveira P.J., Holy J., Oliveira C.R., Wallace K.B. Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell Biol. Toxicol. 2009, 25:227-243.
28. Oliveira P.J., Bjork J.A., Santos M.S., Leino R.L., Froberg M.K., Moreno A.J., Wallace K.B. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol. Appl. Pharmacol. 2004, 200:159-168.
29. Danz E.D., Skramsted J., Henry N., Bennett J.A., Keller R.S. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic. Biol. Med. 2009, 46:1589-1597.
30. Branco A.F., Sampaio S.F., Moreira A.C., Holy J., Wallace K.B., Baldeiras I., Oliveira P.J., Sardao V.A. Differentiation-dependent doxorubicin toxicity on H9c2 cardiomyoblasts. Cardiovasc. Toxicol. 2012, 12:326-340.
31. Campos E.C., O'Connell J.L., Malvestio L.M., Romano M.M., Ramos S.G., Celes M.R., Prado C.M., Simoes M.V., Rossi M.A. Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. Eur. J. Pharmacol. 2011, 670:541-553.
32. Lim C.C., Zuppinger C., Guo X., Kuster G.M., Helmes M., Eppenberger H.M., Suter T.M., Liao R., Sawyer D.B. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J. Biol. Chem. 2004, 279:8290-8299.
33. Frost B.M., Eksborg S., Bjork O., Abrahamsson J., Behrendtz M., Castor A., Forestier E., Lonnerholm G. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med. Pediatr. Oncol. 2002, 38:329-337.
34. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 2006, 1:1112-1116.
35. Wang S., Konorev E.A., Kotamraju S., Joseph J., Kalivendi S., Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J. Biol. Chem. 2004, 279:25535-25543.
36. Yan N., Shi Y. Mechanisms of apoptosis through structural biology. Annu. Rev. Cell Dev. Biol. 2005, 21:35-56.
37. Kitazumi I., Tsukahara M. Regulation of DNA fragmentation: the role of caspases and phosphorylation. FEBS J. 2011, 278:427-441.
38. Boujrad H., Gubkina O., Robert N., Krantic S., Susin S.A. AIF-mediated programmed necrosis: a highly regulated way to die. Cell Cycle 2007, 6:2612-2619.
39. Soldani C., Scovassi A.I. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002, 7:321-328.
40. Wang Y., Zheng D., Wei M., Ma J., Yu Y., Chen R., Lacefield J.C., Xu H., Peng T. Over-expression of calpastatin aggravates cardiotoxicity induced by doxorubicin. Cardiovasc. Res. 2013, 98:381-390.
41. Bien S., Rimmbach C., Neumann H., Niessen J., Reimer E., Ritter C.A., Rosskopf D., Cinatl J., Michaelis M., Schroeder H.W., Kroemer H.K. Doxorubicin-induced cell death requires cathepsin B in HeLa cells. Biochem. Pharmacol. 2010, 80:1466-1477.
42. Mizutani H., Tada-Oikawa S., Hiraku Y., Kojima M., Kawanishi S. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci. 2005, 76:1439-1453.
43. 2+ increase are reciprocally modulated in rat cardiomyocytes. Exp. Mol. Med. 2006, 38:535-545.
44. Kim Y., Ma A.G., Kitta K., Fitch S.N., Ikeda T., Ihara Y., Simon A.R., Evans T., Suzuki Y.J. Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol. Pharmacol. 2003, 63:368-377.
45. Rigor D.L., Bodyak N., Bae S., Choi J.H., Zhang L., Ter-Ovanesyan D., He Z., McMullen J.R., Shioi T., Izumo S., King G.L., Kang P.M. Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase Cbeta2 in the regulation of physiologic developmental hypertrophy and heart function. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H566-H572.
46. Lipton S.A., Bossy-Wetzel E. Dueling activities of AIF in cell death versus survival: DNA binding and redox activity. Cell 2002, 111:147-150.
47. Ye H., Cande C., Stephanou N.C., Jiang S., Gurbuxani S., Larochette N., Daugas E., Garrido C., Kroemer G., Wu H. DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat. Struct. Biol. 2002, 9:680-684.
48. Cande C., Cohen I., Daugas E., Ravagnan L., Larochette N., Zamzami N., Kroemer G. Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie 2002, 84:215-222.
49. Norberg E., Gogvadze V., Vakifahmetoglu H., Orrenius S., Zhivotovsky B. Oxidative modification sensitizes mitochondrial apoptosis-inducing factor to calpain-mediated processing. Free Radic. Biol. Med. 2010, 48:791-797.
50. Chen Q., Paillard M., Gomez L., Ross T., Hu Y., Xu A., Lesnefsky E.J. Activation of mitochondrial mu-calpain increases AIF cleavage in cardiac mitochondria during ischemia-reperfusion. Biochem. Biophys. Res. Commun. 2011, 415:533-538.
51. Ozaki T., Yamashita T., Ishiguro S. Mitochondrial m-calpain plays a role in the release of truncated apoptosis-inducing factor from the mitochondria. Biochim. Biophys. Acta 2009, 1793:1848-1859.
52. Kim B.M., Choi Y.J., Lee Y.H., Joe Y.A., Hong S.H. N, N-Dimethyl phytosphingosine sensitizes HL-60/MX2, a multidrug-resistant variant of HL-60 cells, to doxorubicin-induced cytotoxicity through ROS-mediated release of cytochrome c and AIF. Apoptosis 2010, 15:982-993.
53. Bae S., Siu P.M., Choudhury S., Ke Q., Choi J.H., Koh Y.Y., Kang P.M. Delayed activation of caspase-independent apoptosis during heart failure in transgenic mice overexpressing caspase inhibitor CrmA. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H1374-H1381.
54. Zhuang J., Ma W., Lago C.U., Hwang P.M. Metabolic regulation of oxygen and redox homeostasis by p53: lessons from evolutionary biology?. Free Radic. Biol. Med. 2012, 53:1279-1285.
55. Marchenko N.D., Zaika A., Moll U.M. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J. Biol. Chem. 2000, 275:16202-16212.
56. Moll U.M., Zaika A. Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett. 2001, 493:65-69.
57. Schuler M., Green D.R. Mechanisms of p53-dependent apoptosis. Biochem. Soc. Trans. 2001, 29:684-688.
58. Nithipongvanitch R., Ittarat W., Cole M.P., Tangpong J., Clair D.K., Oberley T.D. Mitochondrial and nuclear p53 localization in cardiomyocytes: redox modulation by doxorubicin (Adriamycin)?. Antioxid. Redox Signal. 2007, 9:1001-1008.
59. Liu N., Wang J., Wang R., Liu Z., Yu Y., Lu H. ING5 is a Tip60 cofactor that acetylates p53 in response to DNA damage. Cancer Res. 2013, 73:3749-3760.
60. Yu S.W., Wang H., Poitras M.F., Coombs C., Bowers W.J., Federoff H.J., Poirier G.G., Dawson T.M., Dawson V.L. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002, 297:259-263.
61. Mehdi S. Cell-penetrating inhibitors of calpain. Trends Biochem. Sci. 1991, 16:150-153.
62. Miseviciene L., Anusevicius Z., Sarlauskas J., Sevrioukova I.F., Cenas N. Redox reactions of the FAD-containing apoptosis-inducing factor (AIF) with quinoidal xenobiotics: a mechanistic study. Arch. Biochem. Biophys. 2011, 512:183-189.
63. Goetzenich A., Hatam N., Zernecke A., Weber C., Czarnotta T., Autschbach R., Christiansen S. Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig. J. Heart Lung Transplant. 2009, 28:1087-1093.
64. Huang C., Zhang X., Ramil J.M., Rikka S., Kim L., Lee Y., Gude N.A., Thistlethwaite P.A., Sussman M.A., Gottlieb R.A., Gustafsson A.B. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation 2010, 121:675-683.
65. De Angelis A., Piegari E., Cappetta D., Marino L., Filippelli A., Berrino L., Ferreira-Martins J., Zheng H., Hosoda T., Rota M., Urbanek K., Kajstura J., Leri A., Rossi F., Anversa P. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2010, 121:276-292.
66. Toldo S., Goehe R.W., Lotrionte M., Mezzaroma E., Sumner E.T., Biondi-Zoccai G.G., Seropian I.M., Van Tassell B.W., Loperfido F., Palazzoni G., Voelkel N.F., Abbate A., Gewirtz D.A. Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse. PLoS One 2013, 8:e58421.
67. Wang L., Liu L., Shi Y., Cao H., Chaturvedi R., Calcutt M.W., Hu T., Ren X., Wilson K.T., Polk D.B., Yan F. Berberine induces caspase-independent cell death in colon tumor cells through activation of apoptosis-inducing factor. PLoS One 2012, 7:e36418.